Vanda (VNDA) Q2 Revenue Rises 4%

Vanda Pharmaceuticals reported a wider Q2 2025 GAAP net loss of $27.2 million (EPS -$0.46), significantly missing analyst estimates, despite a 4% revenue increase to $52.6 million that also fell short of consensus. The increased loss was primarily driven by a 63.5% surge in SG&A costs and a 32% rise in R&D, reflecting substantial investment in Fanapt's commercial expansion, which saw 27% sales growth, and pipeline development. However, this growth was largely offset by sales declines in HETLIOZ and PONVORY due to generic competition and market pressures. The company reaffirmed its full-year revenue and cash guidance, indicating continued strategic spending on future pipeline assets amidst current profitability pressures and product-specific headwinds.

Analysis

Vanda Pharmaceuticals' Q2 2025 results reveal a company in a high-stakes investment phase, marked by a significant disconnect between top-line growth and profitability. While GAAP revenue grew a modest 4% year-over-year to $52.6 million, it fell short of the $54.8 million consensus estimate. More critically, the GAAP net loss widened substantially to $27.2 million, or ($0.46) per share, missing the estimated ($0.36) EPS and marking a 475% decline from the prior year's ($0.08) EPS. This deterioration was driven by a deliberate strategic pivot towards aggressive spending, with SG&A costs surging 63.5% and R&D costs rising 32%. The spending is highly concentrated, fueling the successful commercial relaunch of Fanapt®, whose sales grew an impressive 27% to $29.3 million. However, this single-product strength was insufficient to offset the secular decline of HETLIOZ® (down 13%) and PONVORY® (down 18%) due to generic entry and competitive pressures. The company's cash position decreased by $15.4 million during the quarter, yet management reaffirmed full-year revenue and year-end cash guidance, suggesting confidence in its spending strategy despite the near-term profitability impact. The outlook is now heavily dependent on execution, with upcoming PDUFA dates for Tradipitant and Bysanti™ in late 2025 and early 2026 serving as critical catalysts that must justify the current cash burn and strategic direction.

Key Decisions for Investors

• Investors should scrutinize the return on the 63.5% surge in SG&A spending by tracking if Fanapt®'s sales growth can continue to accelerate and offset the material revenue declines from HETLIOZ® and PONVORY®.
• The investment thesis is now heavily contingent on pipeline execution, making the upcoming PDUFA decision dates for Tradipitant (December 30, 2025) and Bysanti™ (February 21, 2026) key binary events for the stock.
• Monitor the quarterly cash burn against the company's reaffirmed year-end cash guidance of $280-$320 million, as any negative deviation would signal that the current spending level is unsustainable.
• Consider the downside risk from flagged headwinds, including ongoing generic erosion for HETLIOZ® and the future negative gross-to-net impact from the Inflation Reduction Act on key products.